Search results for: rn

September 25th, 2007

Sharing the Learning Curve

I have only been a part of Johnson & Johnson since the beginning of the year, and so I get questions from my friends and family all the time about what it is like now to be working at Johnson & Johnson, “the baby company.” This question is usually followed by a request for baby lotions, beauty products or Band-Aid Brand adhesive bandages.

It can be a steep learning curve coming into Johnson & Johnson and getting up to speed on its many businesses, but as I learn things I hope to share some of my observations with you. I want to provide a voice on JNJBTW that brings a bit of an “outsider’s” perspective.

Johnson & Johnson is no different than most companies in the fact it faces sizable business challenges every day. For example, as a health care company with a pharmaceuticals business, we have to deal with how to replace significant revenues from drugs that will be going off patent and how to handle unprecedented reimbursement challenges for drugs like erythropoiesis-stimulating agents (speaking of my learning curve…).

There is a healthy curiosity and a natural skepticism in the marketplace about how companies, including Johnson & Johnson, can overcome such challenges.

Read More

January 20th, 2015

WW Pharmaceuticals Chairman Joaquin Duato Shares His Leadership Perspectives in PwC’s 18th Annual Global CEO Survey

Joaquin Duato CEO Survey

Editor’s Note:  Joaquin Duato, Worldwide Chairman of our Janssen Pharmaceutical Companies, was asked to participate in the 18th Annual PricewaterhouseCoopers (PwC) LLC Global CEO Survey on behalf of Johnson & Johnson and our senior leadership team. Every year, PwC interviews top global leaders about the global economy and their perspectives on business challenges and opportunities.

This year’s survey focuses on themes such as strategies for business growth, the emergence of digital technology, and talent diversity and adaptability.  The survey results were shared earlier today in Davos, Switzerland on the eve of the Annual Meeting of the World Economic Forum.

We invite you to watch the PwC interview and hear Joaquin’s perspectives on topics including accelerating medical innovation, tech and big data development and addressing global threats such as the Ebola health crisis.

Learn more about Joaquin’s leadership role at Johnson & Johnson by visiting his senior management page bio.

Read More

January 14th, 2015

A new culture in science, a better outcome for public health

By Joanne Waldstreicher, MD, Chief Medical Officer, Johnson & Johnson

Innovation in the interest of public health happens faster when researchers in both the public and private sectors share information and work together. We’ve seen this happening to the greatest extent during the current Ebola epidemic. Imagine if this were the new culture and the new standard in science.  If done responsibly so that we could also maintain a healthy R&D ecosystem, sharing data from clinical studies can help advance the science that is the foundation of all medical care.

Our primary responsibility, as one of the most broadly based healthcare companies in the world, is to the doctors and nurses, patients and consumers, mothers, fathers and children who use our products. That means taking a patient and consumer-centered approach to advancing medical science through all of our products that touch people in different ways. It also means we have the opportunity to set the standard and be leaders and role models in advancing best practices that will ultimately advance science and medicine.

When we announced early last year that we would partner with the Yale School of Medicine Open Data Access Project (YODA) to serve as an independent reviewer for every request for clinical data from our pharmaceutical studies, we broke new ground in data transparency.

Read More

January 6th, 2015

Collaborating to Speed Development of an Ebola Vaccine

By Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Ebola continues to cause suffering among patients, families and health care workers in West Africa.  In response, the world’s scientific, pharmaceutical, regulatory, and public health communities have united in taking action to find new ways to collaborate and drive forward innovations to help prevent Ebola infection.  These collaborative efforts are happening at record pace, and they offer a window into what is possible in the face of a global epidemic.

Speed matters.  To date, almost 8,000 people have died from Ebola and more than 20,000 cases have been reported and the numbers continue to rise.

This sense of urgency has motivated our teams to work day and night in our labs and in close collaboration with partners such as the World Health Organization, U.S. Centers for Disease Control and Prevention, UK Medicines and Healthcare Products Regulatory Agency on finding a solution as fast as possible. Together we are working to accelerate the process of developing, producing and distributing a preventive Ebola vaccine regimen.

As a result of these collaborative efforts, today Johnson & Johnson announced the start of a Phase 1 first-in-human clinical trial of a preventive Ebola vaccine regimen in development at our Janssen Pharmaceutical Companies.

Read More

December 27th, 2014

The 10 Most-read Stories of 2014

Compiled by the Johnson & Johnson Social Media Team

From paying tribute to our military veterans to the continued fight against HIV and AIDS, Johnson & Johnson had a wealth of stories and news to share on a wide range of topics in 2014. Here’s a list of the top 10 JNJ Blog posts that readers clicked on the most. Visit us here in 2015 when we continue the conversation about J&J news and events.

10. Meet Our U.S. Military Veterans

In honor of Veterans Day this year, J&J recognized and thanked all those who served in the military, including our own employees. This post featured 27 employees who are veterans and work across our Pharmaceutical, Medical Devices & Diagnostics and Consumer segments.

9. Healthy Minds Program Explores Major Depressive Disorder

Across the globe, approximately 450 million people suffer from a mental or neurological disorder, yet nearly 60 percent who have a known disorder never consult a doctor to better understand their mental health.

Read More

December 22nd, 2014

Caring for our Heroes

by Susan Can, Senior Director of Corporate Equity and Strategic Partnerships, Johnson & Johnson

We have a very active employee Veterans Leadership Council at Johnson & Johnson, and in partnership with them, we’ve had an exciting year supporting our servicemen and women, and their families in 2014. Here’s a snapshot of the work we’ve done this year:

In February, we were pleased to announce our partnership with American Corporate Partners (ACP), a unique non-profit organization dedicated to assisting U.S. military veterans in their transition from the military to the civilian workforce. Johnson & Johnson Chairman and CEO Alex Gorsky was also featured in a public service announcement encouraging people with business skills to share their valuable experience and guidance at ACP-AdvisorNet because “their service deserves our service.”

In April, Johnson & Johnson signed on to be the Official Healthcare Partner of the USO. Over the course of this three-year partnership, Johnson & Johnson will support and sponsor USO programs that offer direct aid, comfort and support to transitioning troops and their families.

USO Heroes

That same month, we were honored to participate in the official opening of the USO Warrior and Family Center at Naval Support Activity Bethesda, home of Walter Reed National Military Medical.

Read More

December 19th, 2014

When It’s More Than Joint Pain

by Jack L. Groppel, Ph.D., FACSM, Co-Founder, Johnson & Johnson Human Performance Institute, Inc.

When most people think about the effects of osteoarthritis (OA) on their life, they think about how it impacts them physically – how they may not be able to walk long distances anymore, or sit on the ground to play with their grandchildren. But what many don’t consider is the effect OA also has on their emotional, mental and spiritual energy or the quality, focus and force of one’s energy.

I fought joint pain every day for almost three decades, and it took up much of my best energy and left me with little for my family and work. I used to run or play tennis every day. Due to my OA, my personal trainers consistently told me I should not be running, but cycling and swimming instead. But, you see (and here comes the flawed thinking), I was busy. It took too long to change my exercise routine, and I got bored. I loved the action I got from a tennis workout, or from a four-mile run.

Over time, the pain in my knees combined with my desire to push myself physically forced me to give up many of the things I loved.

Read More

December 16th, 2014

Holiday Giving

by Sarah Colamarino, Vice President, Corporate Equity Programs, Johnson & Johnson

As a mother of now two older teenagers, I always struggled to find family activities that could make “giving back” part of our daily lives. I learned that it did not always take a grand gesture to make a difference. Sometimes it’s the simplest of acts that make the biggest difference – volunteering at a soup kitchen; buying a toy for a child in need; donating food to a local food bank. But these activities can sometimes be difficult to find, especially given the hectic pace of the holiday season.

As head of our Corporate Partnerships team, we have worked to identify a few simple activities working with organizations making a difference for children and families. These hopefully will make “giving back” simple yet part of your holiday season. Examples include:

  • Save the Children “Gifts of Joy” Catalog: Save the Children is proud to be the leading expert on children. By selecting a gift through this catalog, you are making a donation to Save the Children and can help give every child the best chance for success, both domestically and globally. Each gift in this catalog is representative of resources, services or support provided by Save the Children to a program area in which we work, and may change due to environmental, programmatic and economic considerations.

Read More

December 15th, 2014

Health Care Sustainability Gets a Shot in the Arm

by Erol Odabasi, Director, MD&D Sustainability, Johnson & Johnson

Sustainable Purchasing among Hospitals is on the Rise

Health Care Sustainability

Vaccine season is in full swing and your local hospital is probably advertising free flu shots. But this fall something’s different. If your provider is like the 300 global health care professionals my company, Johnson & Johnson, and Harris Poll recently surveyed, chances are your hospital has ‘gone green.’

Sustainability in the health care space has been on the rise for some time, and, according to the new study, 54 percent of health care professionals across six countries (United States, United Kingdom, France, Germany, Brazil and Japan) now report their hospital already incorporates sustainability into its purchasing decisions. This means that, in addition to price, quality, and outcomes, a majority of health care purchasers are also evaluating products based on environmental criteria, and that they are looking for products that are more energy efficient, free of materials of concern like PVC (polyvinyl chloride), and have a lower environmental impact after use.

Health Care Sustainability

While this mindset has existed among select practitioners for years, the exciting news is that 80 percent of global respondents now expect their hospitals will consider sustainability when purchasing products within the next two years – a significant increase from the current 54 percent.

Read More

December 11th, 2014

Johnson & Johnson and USAID Partner to Address the Global Health Threat of Antibiotic-Resistant Bacteria

by Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Among my lifelong goals is to advance progress in new treatment options for patients living with the world’s most serious health threats. Antimicrobial resistance is responsible for many of them, especially in communities with limited resources and fragmented healthcare infrastructures. When resistance limits first- and second-line options, healthcare providers must opt for less desirable alternatives,1 which often lead to worsened patient outcomes.

Over many years of researching and learning, the complexities of infectious diseases have become clear to me. Despite the development of new treatments to address ever-expanding forms of antimicrobial resistance, the ability to scale up appropriate use of treatment regimens remains challenging.

According to the 2013 Antibiotic Resistance Threats in the United States report, approximately 250,000 antimicrobial infections each year require hospitalization, or are already affecting hospitalized patients, who also already have weakened immune systems.1 These infections should command our complete attention especially because the threat can reach us all – almost half of infections occur in people younger than 65, and more than 90 percent of deaths occur in people 65 and older.1

Given the hardships of combating antimicrobial resistance, we are proud to announce our pharmaceutical company, Janssen, has signed a memorandum of understanding (MOU) for a collaboration with the United States Agency for International Development (USAID) to help address the global health threat of antibiotic-resistant bacteria.

Read More